Relmada Therapeutics RLMD
NASDAQ RLMD
$3.27 -0.09 (-2.83%)
As of: Oct 21, 2026 · 2:43 PM EDT

Relmada Therapeutics (RLMD) Gross Margin (2012 - 2013)

Updated

Relmada Therapeutics' Gross Margin came in at 21.31% for FY2013, down 5.66 percentage points from 26.97% in FY2012.

Analysis

Relmada Therapeutics (RLMD) Gross Margin (2012 - 2013) Analysis & Trends

  • Per Business Quant, earlier years put Gross Margin at 26.97% in FY2012.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Eli Lilly 1,136.92 Bn 1,105.50 Bn 19.71 Bn 85.78%
2 Johnson & Johnson 617.57 Bn 536.10 Bn 17.26 Bn 68.19%
3 AbbVie 501.37 Bn 474.48 Bn 12.70 Bn 74.74%
4 Merck 367.96 Bn 322.33 Bn 12.21 Bn 73.54%
5 Novartis Ag 297.98 Bn 261.97 Bn 11.24 Bn 78.02%
6 Astrazeneca 261.45 Bn 235.14 Bn 12.86 Bn 83.60%
7 Amgen 236.30 Bn 191.70 Bn 7.24 Bn 72.04%
8 Gilead Sciences 190.27 Bn 164.46 Bn 6.22 Bn 79.76%
9 Pfizer 169.65 Bn 116.29 Bn 10.94 Bn 72.78%
10 Relmada Therapeutics 367.47 Mn -191.12 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Nov 30, 2013 8.86%
May 31, 2013 49.21%
Feb 28, 2013 20.55%
Nov 30, 2012 13.91%
Aug 31, 2012 34.13%
May 31, 2012 27.00%
API Access

Relmada Therapeutics Gross Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gross-margin&ticker=RLMD&period=max&api_key=YOUR_API_KEY